South Korea · Delayed Price · Currency is KRW Tdspharm Statistics
Total Valuation
Tdspharm has a market cap or net worth of KRW 32.68 billion. The enterprise value is 18.82 billion.
| Market Cap | 32.68B |
| Enterprise Value | 18.82B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Tdspharm has 5.53 million shares outstanding. The number of shares has increased by 7.98% in one year.
| Current Share Class | 5.53M |
| Shares Outstanding | 5.53M |
| Shares Change (YoY) | +7.98% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 46.29% |
| Owned by Institutions (%) | 3.95% |
| Float | 2.95M |
Valuation Ratios
The trailing PE ratio is 6.07.
| PE Ratio | 6.07 |
| Forward PE | n/a |
| PS Ratio | 0.99 |
| PB Ratio | 0.73 |
| P/TBV Ratio | 0.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 5.01 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 3.65 |
| EV / Sales | 0.57 |
| EV / EBITDA | 2.96 |
| EV / EBIT | 3.34 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.00, with a Debt / Equity ratio of 0.31.
| Current Ratio | 2.00 |
| Quick Ratio | 1.77 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 2.18 |
| Debt / FCF | -2.30 |
| Interest Coverage | 19.51 |
Financial Efficiency
Return on equity (ROE) is 12.18% and return on invested capital (ROIC) is 13.83%.
| Return on Equity (ROE) | 12.18% |
| Return on Assets (ROA) | 6.20% |
| Return on Invested Capital (ROIC) | 13.83% |
| Return on Capital Employed (ROCE) | 12.52% |
| Weighted Average Cost of Capital (WACC) | 4.85% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.58 |
| Inventory Turnover | 6.74 |
Taxes
In the past 12 months, Tdspharm has paid 1.00 billion in taxes.
| Income Tax | 1.00B |
| Effective Tax Rate | 16.27% |
Stock Price Statistics
The stock price has decreased by -41.66% in the last 52 weeks. The beta is 0.35, so Tdspharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | -41.66% |
| 50-Day Moving Average | 5,714.30 |
| 200-Day Moving Average | 8,091.28 |
| Relative Strength Index (RSI) | 51.27 |
| Average Volume (20 Days) | 41,646 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Tdspharm had revenue of KRW 32.90 billion and earned 5.15 billion in profits. Earnings per share was 973.92.
| Revenue | 32.90B |
| Gross Profit | 9.19B |
| Operating Income | 5.64B |
| Pretax Income | 6.16B |
| Net Income | 5.15B |
| EBITDA | 6.36B |
| EBIT | 5.64B |
| Earnings Per Share (EPS) | 973.92 |
Balance Sheet
The company has 27.76 billion in cash and 13.89 billion in debt, with a net cash position of 13.87 billion or 2,507.56 per share.
| Cash & Cash Equivalents | 27.76B |
| Total Debt | 13.89B |
| Net Cash | 13.87B |
| Net Cash Per Share | 2,507.56 |
| Equity (Book Value) | 44.89B |
| Book Value Per Share | 8,472.25 |
| Working Capital | 18.62B |
Cash Flow
In the last 12 months, operating cash flow was 6.53 billion and capital expenditures -12.56 billion, giving a free cash flow of -6.03 billion.
| Operating Cash Flow | 6.53B |
| Capital Expenditures | -12.56B |
| Depreciation & Amortization | 708.99M |
| Net Borrowing | 7.25B |
| Free Cash Flow | -6.03B |
| FCF Per Share | -1,090.60 |
Margins
Gross margin is 27.94%, with operating and profit margins of 17.14% and 15.67%.
| Gross Margin | 27.94% |
| Operating Margin | 17.14% |
| Pretax Margin | 18.71% |
| Profit Margin | 15.67% |
| EBITDA Margin | 19.34% |
| EBIT Margin | 17.14% |
| FCF Margin | n/a |
Dividends & Yields
Tdspharm does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.98% |
| Shareholder Yield | -7.98% |
| Earnings Yield | 15.77% |
| FCF Yield | -18.45% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Tdspharm has an Altman Z-Score of 3.74 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.74 |
| Piotroski F-Score | 5 |